Latest Conference Articles

Zanidatamab plus chemotherapy with or without bevacizumab showed efficacy and safety in previously untreated HER2-positive metastatic colorectal cancer.

First-line combinations with trastuzumab deruxtecan showed initial efficacy in HER2-positive esophageal, gastric, and gastroesophageal junction cancers.

Adjuvant pembrolizumab and chemotherapy with or without radiation showed mixed findings in patients with high-risk endometrial cancer.

The novel ALK inhibitor NVL-655 demonstrated encouraging activity in heavily pretreated patients with advanced ALK-positive NSCLC.

Nancy U. Lin, MD, discusses the DESTINY-Breast12 trial of T-DXd in patients with HER2-positive metastatic breast cancer with or without brain metastases.

Nicolas Girard, MD, discusses the RELATIVITY-104 trial of nivolumab plus relatlimab and chemotherapy in previously untreated stage IV or recurrent NSCLC.

Amivantamab plus chemotherapy yielded promising OS trends compared with chemotherapy in EGFR-mutant advanced NSCLC after disease progression on osimertinib.

Treatment with belrestotug plus dostarlimab yielded a clinically meaningful improvement in ORR vs dostarlimab monotherapy in unresectable PD-L1–high NSCLC.

T-DXd showcased overall and intracranial activity in patients with HER2-positive metastatic breast cancer with stable and active brain metastases.

The addition of nivolumab to tivozanib did not improve outcomes in metastatic RCC and 1.34 mg of tivozanib monotherapy may be considered as a second-line therapy.

BMS-986012 plus nivolumab and chemotherapy provided a modest PFS benefit but signals of OS improvement in extensive-stage small cell lung cancer.

Belzutifan improved PFS and ORR but failed to deliver a significant improvement in OS vs everolimus in pretreated advanced clear cell renal cell carcinoma.

Breelyn Wilky, MD, discusses updated findings from a phase 1 study investigating botensilimab plus balstilimab in refractory metastatic sarcoma.

Eric Jonasch, MD, discusses preliminary findings from a trial investigating NKT-2152 in previously treated advanced clear cell renal cell carcinoma.

Consistent survival benefit was seen with consolidation durvalumab across subgroups in the ADRIATIC trial affirms its use as a standard of care in LS-SCLC.

Adjuvant durvalumab did not provide a disease-free survival advantage over placebo in patients with NSCLC across different PD-L1 subgroups.

T. Jeroen N. Hiltermann, MD, discusses findings from phase 1/2 ARTEMIDE-01 trial.

Patients with EGFR-mutated NSCLC demonstrated reduced symptom progression when treated with amivantamab plus lazertinib vs osimertinib.

T-DXd showed clinical activity regarding responses and survival outcomes in patients with pretreated HER2-overexpressed metastatic non–small cell lung cancer.

Benjamin Besse, MD, PhD, discusses findings from the phase 3 CARMEN-LC03 trial.

Tusamitamab ravtansine vs docetaxel was not significantly different regarding survival in patients with advanced nonsquamous non–small cell lung cancer.

Taletrectinib was safe and generated durable responses in both TKI-naive and -pretreated patients with ROS1-positive non–small cell lung cancer.

Neoadjuvant durvalumab plus chemotherapy and adjuvant durvalumab improves event-free survival in stage IIA-IIIB resectable non–small cell lung cancer vs. placebo.

Xiuning Le, MD, PhD, discusses updated findings from the phase 1/2 SOHO-01 trial.

The safety profile of adjuvant alectinib was tolerable and manageable in ALK-positive NSCLC.

Tarlatamab demonstrated durable responses and long-term tolerability in patients with previously treated small cell lung cancer.

Rilvegostomig induced responses with acceptable tolerability in patients with checkpoint inhibitor-naive, metastatic NSCLC.

Natasha B. Leighl, MD, BSc, MMSc, discusses patient satisfaction and resource utilization results from the phase 3 PALOMA-3 study.

John V. Heymach, MD, PhD, discusses updated outcomes from the AEGEAN trial of perioperative durvalumab vs placebo in resectable non–small cell lung cancer.

Neoadjuvant pembrolizumab plus chemotherapy led to greater pathologic regression vs placebo plus chemotherapy in early-stage non–small cell lung cancer.